Explore the vast range of titles available.

PurposeNail damage is common amongst patients receiving chemotherapy causing disfigurement and pain. This investigation evaluated whether a topical balm containing steam-extracted, bioactive polyphenolic-rich herbal oils blended with organic waxes could protect the nails via their reported anti-inflammatory, analgesic, anti-oxidant and anti-microbial properties.Methods60 patients (23M, 37F) were randomised to apply (2–3/day) either the plant balm (PB) or a petroleum control (PC) to their nail beds. Demographics, type and number of chemotherapy cycles did not differ between the two groups, recruited between Sept 2015 and Sept 2016. An unpaired t test was used to test the differences in symptoms and physical nail damage between the two groups.ResultsSymptom scores recorded with the dermatology life quality questionnaire (DLQQ) were significantly better, between the start and end of chemotherapy, in the group applying the PB versus PC. Likewise, the mean fall in nail damage, scored with the Nail Psoriasis Index by the supervising physician, was also significantly different.ConclusionThe polyphenolic-rich essential oils and plant-based waxes in this nail bed balm profoundly reduced chemotherapy-related nail damage and improved nail-related quality of life, compared to a control. A further analysis is planned combining this balm with nail bed cooling.

Onycholysis and paronychia has been associated with chemotherapy treatment for women with breast cancer. Our primary aim was to investigate the effectiveness of different topical interventions to ameliorate nail toxicity. Secondary aims were to explore the full range and severity of possible nail changes associated with taxane-based chemotherapy and the specific impact this had on quality of life, using two novel measures. This was an exploratory randomised controlled trial of three topical interventions (standard care, nail polish or specialist nail drops) for the prevention or reduction of nail changes induced by taxane-based chemotherapy. Outcomes included nail toxicity assessed at three time points (baseline, 3 weeks and 3 months post completion of chemotherapy) using two novel clinical tools (NToX-G12, NToX-QoL) and the Common Terminology Criteria for Adverse Events (CTCAE v3) and EQ-5D-5L. A total of 105 women were recruited (35 in each arm) and monitored up to three months post completion of chemotherapy. Almost 20% of patients were over the age of 60 years. There were 26 withdrawals, the majority from the nail polish arm. Residual Maximum Likelihood REML analysis indicated a significant arm, time and interaction effect for each intervention (p < 0.001). Less nail toxicity was observed in patients receiving specialist nail drops or standard care arms in comparison to those using nail polish. This study provides evidence to support clinicians’ suggestions on nail care recommendations based on the patients’ needs and preferences. Future investigations into comparing or combining cryotherapy and topical solutions that can support patient’s decisions are warranted.

Purpose Onycholysis and other nail toxicities occur in approximately 20–30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients’ quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAIL ® solution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities. Methods This study was a prospective, randomized, controlled study of HNS for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide. In the experimental arm, patients painted HNS on nails and periungual areas once a day till developing onycholysis grade 2. After grade 2 onycholysis development, patients applied HNS twice a day regardless of treatment arm. The primary endpoints were the incidence of onycholysis grade 2 and recovery rate from grade 2 onycholysis. Results From August 2015 to May 2016, 103 patients were enrolled and completed this study. Of these, 25 cases of grade 1 and 22 of grade 2 onycholysis were observed. Prophylactic application of HNS resulted in a statistically significant reduction of grade 2 onycholysis compared to controls ( P  = 0.001) and all grade onycholysis was also significantly lower in the experimental arm ( P  = 0.034). Multivariate analysis showed that HNS decreased grade 2 onycholysis (Hazard ratio (HR) 0.366, 95% confidence interval (CI) 0.148, 0.902; P  = 0.029) and all grade onycholysis (HR 0.372, 95% CI 0.201–0.687, P  = 0.002). Conclusions Hydrating nail solution significantly reduced the incidence of docetaxel-induced onycholysis in BC patients (NCT02670603).

Background Hallux Valgus (HV) deformity is associated with misalignment in the sagittal plane that affects the first toe. However, the repercussions of the first toe hyperextension in HV have been scarcely considered. The purpose of this study was to provide evidence of the association between first-toe hyperextension and the risk of first toenail onycholysis in HV. Methods A total of 248 HV from 129 females were included. The extension of 1st MTP joint was measured while the patient was in the neutral position of the hallux using a two-branch goniometer. The classification of the HV severity stage was determined by the Manchester visual scale, and the height of the first toe in the standing position was measured using a digital meter. An interview and clinical examination were performed to collect information on the presence of onycholysis of the first toe. Results Of the 248 HV studied, 100 (40.3%) had onycholysis. A neutral extension > 30 degrees was noted in 110 (44.3%) HV. The incidence of onycholysis was higher in HV type C than in type B ( p  = 0.044). The probability of suffering onycholysis in the right foot was 2.3 times greater when the neutral position was higher than 30 degrees (OR = 2.3; p  = 0.004). However, this was not observed in the left foot ( p  = 0.171). Onycholysis was more frequent in HV with more than 2 cm height of the first toe ( p  < 0.001). For both feet, the probability of suffering onycholysis was greater for each unit increase in hallux height (right foot OR = 9.0402, p  = 0.005; left foot OR = 7.6633, p  = 0.010). Conclusions The incidence of onycholysis appears to be significantly associated with HV showing more than 30º extension, and more than 2 cm height of the first toe. Height and hyperextension of the first toe together with first toenail pathology should be mandatory in the evaluation of HV.

BackgroundDiagnosis and treatment of psoriatic arthritis require attention from specialists. Clinical manifestations of psoriatic arthritis in children are variable.ObjectivesThe purpose of the study: to evaluate the clinical picture of psoriatic arthritis (PsA) in children.MethodsThe case histories of 23 children with psoriatic arthritis aged 3 to 17 years who were treated by a rheumatologist from 2019 to 2022 were analyzed.ResultsProbable psoriatic arthritis was diagnosed in 7 (29%) patients, definite psoriatic arthritis was diagnosed in 16 (71%) patients. At the same time, 12 (53%) children fell ill at the age of up to 7.5 years. In 7 (29%) patients, the disease began with skin lesions, in 16 (71%) patients immediately with articular syndrome. In the group of patients with certain psoriasis, plaque psoriasis was noted, it was detected in 17 (76.3%) children, guttate psoriasis was in 3 (13.5%), isolated psoriasis of the nails in 3 (10.2%) children. In 5 (21.7%) children, lesions of the skin and nail plates were observed. It was noted that psoriatic onychodystrophy was represented by onycholysis, an “oil spot” in the area of fingers and toes in 5 (23%) patients, and thimble symptom was diagnosed in 4 (18.1%) patients. At the onset of the disease, oligoarticular or asymmetric articular syndrome was noted in 65.6% of cases, a symmetrical rheumatoid-like variant in 20.2% of cases, and psoriatic spondylitis in 14.2% of cases. The dynamics of the articular syndrome after 3 years of observation and treatment indicated the development of symmetrical rheumatoid-like arthritis in 41.2% of patients, asymmetric oligoarthritis in 24.1% of children, and spondyloarthritis in 22.1%.ConclusionThe clinical picture of psoriatic arthritis in children is variable. Skin lesions preceded the development of arthritis in children. At the onset of the disease, asymmetric oligoarthritis predominated, followed by transformation into symmetrical rheumatoid-like arthritis.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.

Background: One of the most important dermatologic side effects of doxycycline is photosensitivity. As doxycycline is important for malaria prophylaxis and malaria is mainly spread in countries with high sun radiation, special attention should be paid to this adverse effect. While there are many publications on the phototoxicity of tetracyclines in general, only a few exist focusing on doxycycline. The objective of this systematic review was to summarize all available reports on clinical manifestations, influencing factors like UV dose or dose of medication, and the possibilities of prevention by sun protection. Methods: This review is based on a systematic search in PubMed for articles in English and German and a manual search between 1990 and 2015. Results: The number of publications is low. Clinical symptoms vary from light sunburn-like sensation (burning, erythema) to large-area photodermatitis. Also, onycholysis is possible. The triggering UV spectrum seems to consist mainly of UVA1 (340-400 nm), so UV-protective products should be used that cover this range. Travelers to tropical countries taking doxycycline for malaria prophylaxis need thorough medical counseling to avoid possibly severe phototoxic reactions. Conclusion: Evidence base must be improved for giving advice on appropriate prevention measures to travelers taking doxycycline and having a risk of significant sun exposure.

Objective: We compared ultrasonography (US) with the modified nail psoriasis severity index (mNAPSI) to investigate the nail plate, nail matrix and adjacent tendons in subjects with psoriatic nail disease and to test the hypothesis that nail involvement was specifically linked to extensor tendon enthesopathy. Methods: 86 psoriatic patients (169 nails) and 20 healthy controls (HC) (40 nails) were assessed with both the mNAPSI and US. The thickness of the nail plate, nail matrix region and adjacent extensor tendon were assessed and compared with physical examination findings. Results: A good agreement between clinical and sonographic nail findings was noted (kappa value = 0.52, p < 0.0001). Entheseal thickening of the extensor tendon on US was more frequent in patients with clinical nail disease compared to patients without clinical nail disease in both psoriasis and psoriatic arthritis (38 vs. 16%, p = 0.03, and 47 vs. 19%, p = 0.008, respectively). Nail thickness, nail matrix and adjacent skin thickness were higher in psoriatic patients compared to HC. Conclusion: US and clinical findings show good correlation for the assessment of the nail in psoriatic disease. The demonstration of extensor tendon enthesopathy in both psoriasis and psoriatic arthritis supports the importance of enthesopathy in nail disease pathogenesis whether or not clinical arthritis is present.

Nail disease in psoriasis has been found to be associated with psoriatic arthritis (PsA); however, which subtype of nail disease holds greater relevance to PsA remains unclear. This study was performed to explore the associations between three subtypes of fingernail disease (pitting, onycholysis, and hyperkeratosis) and PsA among patients with psoriasis. Patients with psoriasis attending five dermatology clinics in Shanghai between January 2020 and May 2021 were examined for skin, joint, and fingernail changes. Multivariate logistic regression analyses were utilized to test the strength of associations between subtypes of fingernail disease and PsA. The receiver operator characteristic (ROC) curve with area under curve (AUC) was used to evaluate their accuracies in diagnosing PsA. Sensitivity and specificity were also calculated. Of 1985 patients with psoriasis included, 228 (11.5%) patients were diagnosed with PsA, and the remaining patients were cutaneous-only psoriasis (PsC). One-hundred and fifty-seven (68.9%) patients with PsA and 748 (42.6%) patients with PsC had fingernail disease. Adjusted models showed that onycholysis and hyperkeratosis were the only type of fingernail disease independently associated with PsA. This association was further confirmed by the forward conditional stepwise regression model (OR, 95% CI for onycholysis: 2.34, 1.79 to 4.27, p  < 0.01; for hyperkeratosis: 1.62, 1.12 to 2.66, p  = 0.037). ROC analysis showed that, compared to pitting and hyperkeratosis, onycholysis had higher AUC (0.630) and sensitivity (52.6%). The psoriatic fingernail onycholysis and hyperkeratosis hold greater relevance to PsA than pitting. Clinically, psoriatic patients with fingernail onycholysis and hyperkeratosis should be assessed for arthritis. Key Points • Psoriatic fingernail onycholysis and hyperkeratosis, rather than pitting, are significantly associated with PsA • Clinically, psoriatic patients with fingernail onycholysis and hyperkeratosis should be assessed for arthritis

Background:The Severity of Nail Psoriasis Score (SNAPS; range 0-40: scored one point each for the presence of pitting, onycholysis, hyperkeratosis and/or severe nail disease# in each fingernail) has been utilised to collect data regarding psoriatic nail dystrophy in the Bath Psoriatic Arthritis (PsA) Longitudinal cohort for many years. SNAPS has construct validity in PsA with the modified Nail Psoriasis Severity Index (mNAPSI) as a comparator instrument and appears to be more feasible than mNAPSI with excellent reliability1.Objectives:We aimed to determine if SNAPS could demonstrate longitudinal sensitivity to change in a cohort of patients treated with biological disease modifying anti-rheumatic drugs (bDMARDs) and therefore be utilized prospectively in observational and clinical trial settings.Methods:Patients enrolled in the Bath PsA longitudinal cohort routinely undergo clinical assessments including a 66/68 Swollen and Tender Joint Count (SJC/TJC), Psoriasis Area Severity Index (PASI), Patient Global Assessment (PtGA) and Physician Global Assessment (PhGA), as well as complete patient-reported outcome measures such as the Health Assessment Questionnaire (HAQ) and Dermatology Quality of Life (Derm-QoL). All patients who commenced treatment with Etanercept and had available outcome data at baseline, 3 months and 6 months were included in this retrospective analysis. Baseline demographics were recorded and paired t-tests were utilized to assess the change in SNAPS at 3 and 6 months. The effect size and measurement error of SNAPS in this cohort were measured. Correlations between SNAPS and other outcome measures were assessed using Pearson’s r.Results:Fifty-seven patients (32 male and 25 female) with available data were retrospectively analysed. The mean (±SD) age of the cohort and duration of disease was 61.3 (±11.55) and 13.3 (±10.82) years respectively. The mean SNAPS at baseline was 3.7 (±6.13) and improved to 2.0 (3.74, p=0.018) at 3 months and 1.2 (2.40) at 6 months (p=0.001 for change from baseline and p=0.039 for change from month 3). The smallest detectable difference at 3 months for SNAPS in this cohort was 1.35, representing 3.37% of the range of the score (Table 2). The standardised response mean (SRM) was 0.32 at 3 months and 0.44 at 6 months. There was a modest correlation between the improvement in the SNAPS score and the improvement in PASI and Derm QOL at 3 months (r = 0.511 and 0.558 respectively, p=0.001) and 6 months (r= 0.672, p<0.001 and r=0.510, p=0.003 respectively).Conclusion:SNAPS demonstrates sensitivity to change in response to treatment with a bDMARD and could be a potential outcome measure for the assessment of treatment efficacy in prospective studies.References:[1]Antony A, Hart D, Cavill C, Korendowych E, McHugh N, Lovell C, Tillett W. The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).Table 1.Outcomes at Baseline, 3 months and 6 monthsMean (SD) or Median [IQR] Baseline3 Months(p for change from baseline)6 Months(p for change from baseline)PASI (0-72)3.0 (4.80)1.6 (2.12) p=0.011.3 (1.6) p=0.002SNAPS (0-40)3.7 (6.13)2.0 (3.73) p=0.0181.2 (2.39) p=0.001Derm-QoL (0-30)5.7 (7.07)1.95 (3.23) p=0.001 (n=33)1.9(4.72) p=0.037 (n=31)Table 2.Measurement Error for SNAPS in an Etanercept CohortTimeframeStandardised Response MeanStandard Error of MeanSmallest Detectable ChangeSmallest Detectable Change (% of total score)Smallest Detectable DifferenceSmallest Detectable Difference (% of total score)0-3 months0.320.691.914.771.353.370-6 months0.440.742.065.151.463.64Disclosure of Interests:Anna Antony: None declared, Sadaf Saeed: None declared, Darren Hart: None declared, Preeti Nair: None declared, Charlotte Cavill: None declared, Eleanor Korendowych: None declared, Neil McHugh: None declared, Christopher Lovell: None declared, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB

We report a 7-year-old girl born with pyloric atresia but without congenital epidermolysis bullosa or skin fragility. Nail dysplasia developed at age 8 months and throughout childhood she suffered from onycholysis and mild nail hypertrophy. Whole-exome sequencing demonstrated biallelic mutations in alpha6 integrin (ITGA6): p. Q139* and R153W. ITGA6 normally forms a protein heterodimer with beta4 integrin (ITGB4), and this dimer participates in anchoring the basal skin cells to the extracellular matrix. Biallelic mutations in each gene are well known to cause epidermolysis bullosa and pyloric atresia. However, this child had ostensibly normal skin without any evidence of skin fragility. In a literature search, we identified 11 cases involving ITGA6 mutations, and all had epidermolysis skin changes. Thus, this case adds to the reported phenotype of ITGA6 disease since it is the first to show absence of an epidermolysis bullosa phenotype in the setting of pyloric atresia and nail dysplasia.